Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

Key Takeaways
Manufacturability is now a capital signal, not a downstream technical detail, as investors increasingly evaluate CMC readiness alongside clinical data during diligence.
FDA transparency around complete response letters has exposed manufacturing deficiencies as a recurring cause of regulatory failure, making CMC risk visible and searchable.
Investors are interrogating scale-up feasibility, process robustness, and GMP readiness earlier, treating manufacturing uncertainty as a material execution risk.
CDMOs play an expanding role as diligence enablers and credibility anchors, helping sponsors translate CMC strategy into investor-legible risk narratives.
Early CMC planning is about credibility, not speed, and is increasingly intertwined with capital-raising strategy in a constrained funding environment.

Introduction: Capital Discipline Has a Manufacturing Signature

Investor selectivity has intensified across biopharma, but the focus of diligence has shifted in a subtle but consequential way. Capital providers are no longer evaluating programs solely through the lens of scientific novelty or clinical promise. Increasingly, questions about how a therapy will be made (e.g., reliably, repeatably, and at scale) are entering the investment conversation far earlier than they did in the past. This shift reflects a broader tightening of capital discipline, in which sources of execution risk that were previously deferred are now scrutinized up front.

Within that context, chemistry, manufacturing, and controls (CMC) has moved from a downstream technical function to an explicit diligence lens. Investor and licensor evaluations now routinely include structured assessments of CMC-related issues, treating manufacturability as an integral component of asset quality rather than an operational detail to be resolved after financing. The implication is not that scientific merit has diminished in importance but that it is no longer sufficient on its own to justify investment.

Manufacturing uncertainty has taken on new significance. Unclear or poorly articulated manufacturing plans, especially for clinical material, are increasingly recognized as early warning signals during diligence, capable of undermining confidence even when the underlying biology appears sound. In practical terms, this means that manufacturability is now interpreted as a capital risk, not merely a development inconvenience.

These dynamics point to a change in investor posture. In a capital-constrained environment, there is far less tolerance for the assumption that manufacturing challenges will be “figured out later.” Instead, investors are signaling — implicitly and explicitly — that credible plans for making a drug are part of the value proposition from the outset, shaping how risk is assessed and how capital is allocated.

What Investors Are Actually Interrogating When They Ask About Manufacturing

When investors probe manufacturing during diligence, they are not asking abstract or hypothetical questions. The focus is practical and execution-oriented, centered on whether a program can move predictably from laboratory development into clinical and ultimately commercial production. Assessing the realism of scale-up plans has become a routine part of investment evaluation, reflecting concern not just about whether a therapy works, but whether it can be produced in a way that supports development timelines and downstream value creation.

This scrutiny often surfaces early. Sophisticated investors are attuned to manufacturing and supply chain vulnerabilities and are increasingly able to identify weaknesses well before a company reaches late-stage development. Issues related to process robustness, sourcing constraints, or scale-dependent variability are no longer viewed as distant risks; they are examined as near-term execution challenges that can materially affect both cost and timing. In this sense, manufacturability functions as a proxy for operational maturity.

As a result, CMC has become a formal category within technical diligence rather than an informal extension of scientific review. Evaluations now explicitly examine manufacturing processes, formulation stability, and scalability as discrete factors, with the goal of determining whether the underlying development strategy is technically sound and aligned with regulatory expectations. These assessments are not limited to internal capabilities. Investors frequently request CMC-specific diligence that extends to external partners, including evaluations of manufacturing organizations’ capacity, track record, and readiness to operate under good manufacturing practice (GMP) requirements appropriate to later stages of development.

There is also concrete evidence that this shift is influencing how investment decisions are made. Venture firms have commissioned formal evaluations of phase III CMC readiness as part of diligence processes, treating manufacturing preparedness as a decision-relevant input rather than a downstream operational detail. Such evaluations underscore that manufacturing risk is being isolated, analyzed, and weighed alongside clinical and regulatory considerations.

Taken together, these practices reflect a broader change in mindset. Manufacturing competence is no longer inferred from the quality of the science or the strength of early clinical data. Instead, it is independently interrogated, with investors seeking explicit evidence that a program’s technical foundations can support its ambitions at scale.

Why This Shift Is Rational: Regulatory Failure Is Often a Manufacturing Failure

The growing investor focus on manufacturability is not speculative; it is grounded in a clearer and more accessible regulatory record than at any point in the past. In recent years, the U.S. Food and Drug Administration (FDA) has fundamentally changed the information environment around regulatory failure, making it easier to see where development programs break down and why. As part of a transparency initiative, the agency has published more than 200 complete response letters (CRLs) associated with applications submitted between 2020 and 2024, offering an unprecedented window into the reasons products fail to secure approval on their first attempt.¹

Importantly, these materials are no longer fragmented or difficult to access. CRLs are now available through a centralized openFDA dataset, which defines its coverage period as 2020–2024 and makes the letters searchable and analyzable as a group rather than as isolated events.^2,3 This shift has transformed CRLs from anecdotal cautionary tales into a body of evidence that can be examined for recurring themes and failure modes.

Within that evidence, manufacturing deficiencies appear explicitly and repeatedly. The FDA has stated that CRLs are most often issued for reasons related to safety and efficacy concerns, manufacturing deficiencies, and bioequivalence issues, placing manufacturing on equal footing with clinical shortcomings as a driver of regulatory non-approval.1For investors, this framing matters. It confirms that manufacturing problems are not peripheral or rare, but a recognized category of regulatory risk with direct consequences for development timelines and asset value.

As a result, investors no longer need to speculate about where regulatory blind spots might lie. Manufacturing failures are now visible, searchable, and increasingly pattern-recognizable within the regulatory record itself. In a market shaped by capital discipline, this transparency makes it rational (if not unavoidable) for investors to treat manufacturability as a core diligence consideration rather than a downstream technical concern.

Quantifying the Risk: Manufacturing Deficiencies Dominate Recent CRLs

Beyond qualitative signals, the regulatory record now provides quantitative context that helps explain why investors have recalibrated their diligence priorities. Analyses of recently released CRLs suggest that manufacturing-related deficiencies are not edge cases but a dominant feature of regulatory rejection outcomes.

Third-party reviews of the CRLs published by the FDA for applications submitted between 2020 and 2024 indicate that quality and manufacturing issues appear with striking frequency. One analysis examining 202 CRLs from this period concluded that approximately 74% involved deficiencies related to quality or manufacturing, encompassing issues such as process control, facility readiness, and broader CMC concerns.⁴ An independent compliance-focused review characterizes the data set in similar terms, likewise identifying CMC and manufacturing deficiencies as a predominant theme across recent CRLs.⁵ While these analyses apply their own categorization frameworks, they converge on the same conclusion: manufacturing risk is not a marginal contributor to regulatory failure.

This pattern is not entirely new, but its visibility has increased. An earlier FDA retrospective review of rejected new molecular entity applications submitted between 2000 and 2012 classified approximately 15% of complete response letters as involving CMC and/or labeling issues.⁶ Although the absolute proportion differs from more recent analyses — reflecting differences in time period, product mix, and classification methodology — the presence of manufacturing-related deficiencies across both data sets underscores their persistent role in regulatory outcomes.

Taken together, these data points help explain why manufacturability has become such a salient diligence concern. Regardless of how individual categories are defined, manufacturing issues appear consistently and materially in regulatory rejection outcomes. For investors seeking to manage downside risk in a more transparent regulatory environment, these patterns reinforce the logic of interrogating manufacturing readiness early, rather than assuming it can be resolved later without consequence.

The Information Asymmetry Problem — and Why It Collapsed

For much of the past two decades, investors operated in an environment marked by significant information asymmetry around regulatory failure. While sponsors disclosed that an application had not been approved, the specific reasons behind that outcome were often only partially visible to the market. This opacity limited investors’ ability to distinguish between remediable setbacks and structural flaws, including those rooted in manufacturing and CMC.

Recent disclosures by the FDA make clear how substantial that information gap once was. According to the agency, sponsors historically avoided mentioning the vast majority of FDA safety and efficacy concerns when publicly announcing non-approval decisions, omitting approximately 85% of such issues from their communications.¹ In addition, when the FDA called for a new clinical trial to address safety or efficacy questions, that requirement went undisclosed roughly 40% of the time.¹ These figures illustrate how little of the regulatory dialogue was visible to external stakeholders, even in high-profile development programs.

The collapse of this asymmetry did not occur quietly. Independent reporting has reinforced the FDA’s own account of historical disclosure practices, confirming the scale of the information previously withheld from investors and the broader market.⁷ Together, these disclosures have reframed how regulatory risk is understood, shifting it from a largely narrative-driven domain to one grounded in documentary evidence.

This change has important implications for manufacturing risk in particular. When the reasons for regulatory failure were opaque, it was easier for manufacturing deficiencies to be minimized, deferred, or subsumed under more general explanations. With the publication of complete response letters and the accompanying transparency initiative, that ambiguity has largely disappeared. Manufacturing risk, once obscured by selective disclosure, is now visible in the regulatory record itself. In doing so, transparency has removed plausible deniability for both sponsors and investors, forcing a more direct reckoning with manufacturability as a material driver of development and capital risk.

Where CDMOs Enter the Capital Equation

As investors sharpen their focus on manufacturability, contract development and manufacturing organizations (CDMOs) have taken on a more consequential role in the investment narrative. No longer viewed solely as outsourced service providers, CDMOs increasingly function as points of technical validation during diligence, helping investors assess whether a development program’s manufacturing ambitions are credible in practice. This shift reflects the growing recognition that manufacturing risk cannot be evaluated in the abstract; it must be grounded in real capabilities, facilities, and execution pathways.

In that context, CDMOs often serve as diligence enablers. Evidence from investor-facing discussions suggests that companies able to walk prospective investors through CDMO facilities actively producing clinical batches are more likely to attract substantial investment or licensing interest.⁸ These interactions provide tangible proof that manufacturing plans are not merely theoretical, allowing investors to see how processes are implemented, controlled, and scaled in real operating environments. The presence of an established CDMO relationship can therefore reduce uncertainty at a stage when many other aspects of development remain inherently speculative.

Beyond facilities and equipment, CDMOs also act as credibility anchors in CMC diligence. Investors increasingly evaluate not only a sponsor’s internal plans but also the capabilities of its manufacturing partners, including their experience, track record, and readiness to operate under GMP conditions appropriate to later-stage development.⁹ In this way, partner selection itself becomes a signal, conveying information about how seriously a company has approached manufacturability and regulatory alignment.

Importantly, this scrutiny does not imply that investors expect early-stage companies to be manufacturing-ready in a comprehensive sense. Rather, expectations are calibrated to development stage. Investors recognize that full commercial readiness is neither realistic nor necessary at the outset, but they do expect credible, phase-appropriate CMC roadmaps that demonstrate how manufacturing will evolve alongside clinical progress.¹⁰ CDMOs play a central role in shaping and substantiating these roadmaps, translating long-term manufacturing requirements into actionable near-term plans.

Taken together, these dynamics underscore a broader reframing of the CDMO’s role in the capital equation. CDMOs are increasingly valued not just for execution capacity but as sources of evidence that help convert manufacturing strategy into something investors can evaluate, trust, and ultimately underwrite.

The Strategic Implication for CDMOs: From Capacity Providers to Risk Translators

Taken together, the preceding dynamics point to a strategic inflection point for CDMOs. As capital discipline tightens and manufacturing risk becomes more visible, CDMOs find themselves operating at the intersection of three converging pressures: investor demand for proof that a program can be manufactured, regulatory evidence that manufacturing failures are common and consequential, and sponsor need for external technical credibility early in development.^1,8,11

In this environment, the traditional framing of CDMOs as providers of capacity is no longer sufficient. Capacity answers the question of where a product might be made; investors are increasingly concerned with how and whether it can be made in a way that supports development milestones, regulatory expectations, and capital efficiency. That shift elevates the strategic value of CDMOs that can help translate CMC complexity into risk narratives that are legible to non-technical stakeholders, particularly investors conducting diligence under heightened scrutiny.

The most strategically positioned CDMOs are therefore those that engage beyond execution. Rather than entering only once a sponsor has finalized its development path, these organizations support diligence itself by articulating manufacturing assumptions, identifying scale-dependent risks, and clarifying what is known versus what remains to be resolved at a given stage. In doing so, they help prevent manufacturability from emerging later as an unanticipated red flag, when corrective action is more expensive and more disruptive to capital plans.

This evolution reframes the CDMO’s role within the broader biopharma ecosystem. By engaging earlier and more strategically, CDMOs can function as translators of risk rather than passive recipients of specifications, aligning manufacturing realities with investor expectations and regulatory evidence. In a market where manufacturability has become a visible signal of asset quality, that ability to bridge technical detail and capital decision-making is increasingly where durable strategic value lies.

What This Means for Sponsors Planning to Raise Capital

For sponsors preparing to raise capital, the implications of this shift are practical and immediate. Manufacturing uncertainty is no longer a neutral omission that can be deferred to later stages of development. As investor diligence increasingly incorporates structured assessment of CMC, gaps or ambiguities in manufacturing plans are more likely to be interpreted as indicators of execution risk rather than as routine early-stage incompleteness. In this environment, silence around manufacturability can work against a company, even when the underlying science is compelling.

This reframing changes the purpose of early CMC planning. The objective is not to accelerate development prematurely or to signal full manufacturing readiness before it is appropriate. Instead, early attention to CMC serves as a credibility exercise, demonstrating that the sponsor understands the technical and regulatory demands ahead and has a coherent plan for addressing them as the program advances. Investors are less concerned with polished solutions than with evidence of disciplined thinking and realistic sequencing.

As a result, engagement with CDMOs is increasingly intertwined with capital strategy. CDMO relationships now function not only as development enablers but as part of the narrative sponsors present to investors, signaling how manufacturing risk will be managed and validated over time.For sponsors seeking funding in a capital-constrained market, the ability to articulate a phase-appropriate CMC roadmap supported by credible manufacturing partners has become an integral component of how value and risk are assessed during financing discussions.

Conclusion: Manufacturability Is Now a Capital Signal

Taken together, the evidence points to a durable shift in how capital evaluates biopharma risk. Investors are focusing on manufacturability earlier not because manufacturing has suddenly become more difficult, but because failure in this domain has proven to be both common and consequential. Regulatory records now make clear that manufacturing deficiencies are a recurring driver of non-approval outcomes, placing CMC on the same footing as safety and efficacy when it comes to understanding why programs stall or fail.^1,4

Regulatory transparency has been central to this change. By publishing CRLs and consolidating them into accessible datasets, the FDA has collapsed much of the information gap that once obscured the true causes of regulatory failure. What was previously hidden behind selective disclosure is now visible, searchable, and analyzable. In that environment, it is no longer rational for investors to treat manufacturability as a downstream concern; the regulatory record itself demonstrates that manufacturing risk is material and persistent.

As a result, manufacturability has become a capital signal rather than a purely technical consideration. Investors are using it to assess execution risk, development credibility, and the likelihood that a program can progress without costly delays or setbacks. Within this framework, CDMOs play a structural role. By providing evidence of manufacturing feasibility, partner capability, and phase-appropriate planning, CDMOs influence how risk is assessed, priced, and mitigated during investment decisions.

The implication for the sector is clear. In a capital-disciplined market shaped by regulatory transparency, manufacturability is no longer something to be explained away later. It is an early, visible signal of asset quality that increasingly shapes how capital flows and how value is defined across biopharma development.